LPA and cardiovascular disorder: However, recent advancements, including the evaluation of antisense therapy targeting the mRNA of apolipoprotein(a) [apo(a)], have sparked immense interest and an evolving body of literature on Lp(a) as a risk factor for cardiovascular diseases.